29 research outputs found
Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review
No full text<b><i>Background:</i></b> Limited data are available for the use of agents in metastatic castration-resistant prostate cancer (mCRPC) beyond the third-line. We provide data during treatment with cabazitaxel (CAB), helping to improve the informed-consent process. <b><i>Patients and Methods:</i></b> We retrospectively reviewed patients treated with fourth-line or beyond CAB for mCRPC after failure of previous therapies with docetaxel, abiraterone acetate, enzalutamide and/or radium-223. The progression-free survival (PFS) and the overall survival (OS) were estimated using the Kaplan-Meier method and compared to published data based on a structured literature review. The hospitalization rate was recorded. Factors influencing 6-months OS were analyzed. <b><i>Results:</i></b> Fifteen patients were identified at 4 institutions and included in the analysis. The median PFS was 104 days (range 47-397 days). The median time to death was 10 months (range 2-16). PFS and OS data are in accordance with 17 published patients so far. During the therapy, eleven (73%) of the patients were hospitalized. Prostate-specific antigen (PSA, 500 units; hazards ratio [HR] 1.491, 95% CI 1.000-2.0175), white blood cell count (HR 0.425, 95% CI 0.108-0.952), hemoglobin (HR 0.6014, 95% CI 0.2942-1.0758), and alkaline phosphatase (100 units; HR 1.0964, 95% CI 1.000-1.2859) correlate with 6-months OS. <b><i>Conclusions:</i></b> CAB beyond the third-line is often accompanied by hospitalization. PFS is a significant proportion of the median time of OS. The baseline laboratory might be a good indicator for the decision between CAB and best-supportive care.</jats:p
Abstract OT2-05-02: A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro
No full textAbstract
Background
Chemotherapy (CTx) is a cornerstone in HR+/HER2- advanced/metastatic breast cancer (a/mBC) after failure of endocrine treatment. In this indication, vinorelbine (VRL) is a well-established cytotoxic drug. There is a high medical need for new options that prolong the time between endocrine failure and intensive CTx, which is commonly associated with impaired quality of life and serious side effects. Metronomic CTx was shown to induce disease control in a/mBC with a favorable safety profile. This innovative approach involving continuous daily dosing of oral VRL, which could provide anti-angiogenic and immune-modulatory properties, has not been investigated so far in this indication.
Trial Design
VinoMetro is an open-label, single-arm, phase II study (Simon two-stage minimax) of metronomic daily oral VRL (30 mg/day) as first-line CTx. The study involves strict safety monitoring with an initial safety run-in. It is accompanied by a steering committee and supervised by an independent data safety and monitoring board (DSMB). The main objectives are to estimate efficacy in terms of clinical benefit rate after 24 weeks of treatment (primary endpoint) and the progression-free survival, amongst others, as well as the assessment of safety and quality of life. Patients with HR+/HER2- a/mBC having failed or being no candidate for endocrine therapy (targeted combinations allowed) and being naïve to palliative CTx are eligible, if they exhibit ECOG 0-1. The main exclusion criteria are prior vinca-alkaloids, aggressive disease requiring combination CTx and CNS involvement.
Until 2017-05-31, 7 patients were enrolled. It is planned to include 45 (39 evaluable) patients at 8 German sites until 09/2018. Scheduled completion date is 09/2019. Two interim analyses are planned (first analysis: safety evaluation based on the 10 initial patients with predefined stopping rules). Depending on recruitment, it is planned to include the interim safety data in the congress presentation.
VinoMetro is an investigator initiated trial (NCT03007992) sponsored by the University Medical Centre of Johannes Gutenberg-University Mainz, Germany, and supported by an unrestricted grant provided by Pierre Fabre Pharma GmbH (Freiburg, Germany).
Citation Format: Schmidt M, Decker T, Fehm T, Fuxius S, Harbeck N, Juhasz-Böss I, Thomssen C, Seehase M, Schollenberger L, Ruckes C, Möbus V. A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - VinoMetro [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-05-02.</jats:p
COMMENTARIUS IN FUXII GRADUM AD PARNASSUM AD USUM DISCIPULORUM
No full textIoannes Fuxius per Aevum quod dicitur Baroccum, quo tempore gustus musici celeriter mutabantur, musicum enchiridion palmare, cui titulus Gradus ad Parnassum, edidit. Quo libro modos musicos componendi ratio aetate artium renatarum exorta cum ratione aevo Barocco usitata coniungitur. Auctor historiam artis musicae, vocabula artis propria, normas hoc opere docet per dialogum Latinum et faberrime scriptum, qui inter Palestrinae personam et eam discipuli personam, quam auctor ipse agit, habetur. At nostris temporibus Fuxius innotuit, quod quasi ante omnium oculos regulas uniuscuiusque Speciei Contrapuncti posuit. Liber eius igitur in multos sermones vernaculos est versus etiam paucis annis post primam divulgationem. Nunc temporis quoque in scholis musicis in omnibus orbis terrarum partibus sitis docetur. Hanc commentatiunculam paravi in usum discipulorum qui capita, ubi Species Contrapuncti duarum vocum enodantur, Latino sermone primigenio atque perlucido legere vellent.
During the Baroque Era, a time of quickly-changing musical tastes, Johann Fux wrote a seminal music composition textbook, the Gradus ad Parnassum, that bridges the gap between Renaissance Counterpoint and High Baroque Style. Through the beautifully-written, Latin dialog between a teacher (in the persona of Palestrina) and a student (Fux himself), the author teaches the reader about the history, nomenclature and norms of composition. Today the name Fux is synonymous with Species Counterpoint and his celebrated text, translated into many vernacular languages within years of its first publication, is read in music-theory classrooms around the world. This commentary is prepared for the use of students who wish to read the chapters on two-voice Species Counterpoint in the original, and highly accessible Latin
Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/plasma – what is a useful tool in clinical studies of anti-angiogenic drugs?
No full text
Weekly docetaxel rechallenge in patients with hormone-resistant prostate cancer refractory to conventionally three weekly docetaxel.
No full textFrühzeitiger Chromogranin A Anstieg bei CRPC Patienten unter Docetaxel Therapie ist mit einem schlechten Gesamt- und Progressionsfreiem Überleben assoziiert
No full textEvaluation Of Metal-ion Stress In Sunflower (helianthus Annuus L.) Leaves Through Proteomic Changes
No full textIn this work, sunflowers (Helianthus annuus L.) were cultivated using soil and vermicompost as substrate, and plant irrigation was carried out using either a Zn solution or a mixed ions solution (Cd, Cu, Pb and Zn). After plant harvesting, the effects of metal-ion contamination on proteins expression (either up- or down-regulation) in sunflower leaves were evaluated using two-dimensional electrophoresis (2-DE), gel images and mass spectrometry (MALDI-QTOF MS). When Zn or mixed ions solution was added to the substrate, nine proteins showed different expressions. Another twenty-three protein spots also showed considerable variation when both treatments (Zn or mixed ions) were applied. Twelve of these proteins were successfully characterized, six of them being reported for the first time in Helianthus annuus L. Two other proteins showed new sequences that have been downloaded to the protein databank. © The Royal Society of Chemistry 2009.11107113Gopal, R., Rizvi, A.H., (2008) Chemosphere, 70, pp. 1539-1544Garcia, J.S., De Magalhães, C.S., Arruda, M.A.Z., (2006) Talanta, 69, pp. 1-15Sousa, A.I., Caador, I., Lillebø, A.I., Pardal, M.A., (2008) Chemosphere, 70, pp. 850-857Benavides, M.P., Gallego, S.M., Tomaro, M.L., (2005) Braz. J. Plant Physiol., 17, pp. 21-34Gratão, P.L., Polle, A., Lea, P.J., Azevedo, R.A., (2005) Funct. Plant Biol., 32, pp. 481-494Arora, A., Sairam, R.K., Srivastava, G.C., (2002) Curr. Sci. India, 82, pp. 1227-1238Ahsan, N., Lee, D.G., Lee, S.H., Kang, K.Y., Lee, J.J., Kim, P.J., Yoon, H.S., Lee, B.H., (2007) Chemosphere, 67, pp. 1182-1193Caruso, G., Cavaliere, C., Guarino, C., Gubbiotti, R., Foglia, P., Lagana, A., (2008) Anal. Bioanal. Chem., 391, pp. 381-391Labra, M., Gianazza, E., Waitt, R., Eberini, I., Sozzi, A., Regondi, S., Grassi, F., Agradi, E., (2006) Chemosphere, 62, pp. 1234-1244Sussulini, A., Souza, G.H.M.F., Eberlin, M.N., Arruda, M.A.Z., (2007) J. Anal. At. Spectrom., 22, pp. 1501-1506Garcia, J.S., Gratão, P.L., Azevedo, R.A., Arruda, M.A.Z., (2006) J. Agric. Food Chem., 54, pp. 8623-8630Bradford, M.M., (1976) Anal. Biochem., 72, pp. 248-254Berkelman, T., Stenstedt, T., (1998) 2-D Electrophoresis - Principles and Methods, , Amersham Biosciences, UppsalaCandiano, G., Bruschi, M., Musante, L., Santucci, L., Ghiggeri, G.M., Carnemolla, B., Orecchia, P., Righetti, P.G., (2004) Electrophoresis, 25, pp. 1327-1333Onnerfjord, P., Ekstrom, S., Bergquist, J., Nilsson, J., Laurell, T., Marko-Varga, G., (1999) Rapid Commun. Mass Spectrom., 13, pp. 315-322Granvogl, B., Plöscher, M., Eichacker, L.A., (2007) Anal. Bioanal. Chem., 389, pp. 991-1002Childs, K.L., Hamilton, J.P., Zhu, W., Ly, E., Cheung, F., Wu, H., Rabinowicz, P.D., Chan, A.P., (2007) Nucleic Acids Res., 35, pp. 846-D85Parker, R., Flowers, T.J., Moore, A.L., Harpham, N.V.J., (2006) J. Exp. Bot., 57, pp. 1109-1118Eravci, M., Fuxius, S., Broedel, O., Weist, S., Eravci, S., Mansmann, U., Schuter, H., Baumgartner, A., (2007) Proteomics, 7, pp. 513-523Dea-Wook, K., Rakwai, R., Agrawal, G.K., Young-Ho, J., Shibato, J., Nam-Soo, J., Iwahashi, Y., Usui, K., (2005) Electrophoresis, 26, pp. 4521-4539Sarry, J.E., Kuhn, L., Ducruix, C., Lafaye, A., Junot, C., Hugouvieux, V., Jourdain, A., Bourguignon, J., (2006) Proteomics, 6, pp. 2180-2198Tuomainen, M.H., Nunan, N., Lehesranta, S.J., Tervahauta, A.I., Hassinen, V.H., Schat, H., Koistinen, K.M., Kärenlampi, S.O., (2006) Proteomics, 6, pp. 3696-3706. , http://www.expasy.org, Expasy Proteomics Server-Aina, R., Labra, M., Fumagalli, P., Vannini, C., Marsoni, M., Cucchi, U., Bracale, M., Citterio, S., (2007) Environ. Exp. Bot., 59, pp. 381-392Roth, U., Von Roepenack-Lahaye, E., Clemens, S., (2006) J. Exp. Bot., 57, pp. 4003-401
PERFORM: An epidemiological, prospective cohort study for patients with HR+/HER2- advanced breast cancer treated 1st-line with an endocrine-based palbociclib combination therapy in real world in Germany and Austria
No full text
